The threshold of CAG repeat expansion in the HTT gene that causes HD is 36 CAG repeats, although ‘superlong’ expansions are found in individual neurons in post mortem brains. Previously, we showed that, compared to mice with <250 CAG repeats, disease onset in R6/2 mice carrying superlong (>440) CAG repeat expansions was delayed, and disease progression was slower. Inclusion pathology also differed from 250 CAG repeat mice, being dominated by a novel kind of extranuclear neuronal inclusion (nENNI) that resembles a class of aggregate seen in patients with the adult onset form of HD.
Objective and methods:
Here, we characterised neuropathology in R6/2 mice with >400 CAG repeats using light and electron microscopy.
Results:
nENNIs were found with increased frequency and wider distribution with age. Some nENNIs appear to ‘mature’ as the disease develops, developing a multi-layered cored structure. Mice with superlong CAG repeats do not develop clinical signs until they are around 30–40 weeks of age, and they attain a normal life span (>2 years). Nevertheless, they show brain atrophy and unequivocal neuron loss from the striatum and cortex by 22 weeks of age, an age at which similar pathology is seen in 250 CAG repeat mice.
Conclusions:
Since this time-point is ‘end stage’ for a 250 CAG mouse, but very far (at least 18 months) from end stage for a > 440 CAG repeat mouse, our data confirm that the appearance of clinical signs, the formation of inclusions, and neurodegeneration are processes that progress independently. A better understanding of the relationship between CAG repeat length, neurodegenerative pathways, and clinical behavioural signs is essential, if we are to find strategies to delay or reverse the course of this disease.
Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–83.
DiFigliaM, SappE, ChaseKO, DaviesSW, BatesGP, VonsattelJP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990–3.
5.
SappE, PenneyJ, YoungA, AroninN, VonsattelJp, DiFigliaM. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol. 1999;58(4):165–73.
MortonAJ, LaganMA, SkepperJN, DunnettSB. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington’s disease mutation. J Neurocytol. 2000;29(9):679–702.
9.
MortonAJ, GlynnD, LeavensW, ZhengZ, FaullRL, SkepperJN, et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis. 2009;33(3):331–41.
10.
Maat-SchiemanM, RoosR, LosekootM, DorsmanJ, Welling-GraaflandC, Hegeman-KleinnI, et al. Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington’s disease. Brain Pathol. 2007;17(1):31–7.
11.
OrdwayJM, Tallaksen-GreeneS, GutekunstCA, BernsteinEM, CearleyJA, WienerHW, et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell. 1997;91(6):753–63.
12.
CooperJK, SchillingG, PetersMF, HerringWJ, SharpAH, KaminskyZ, et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet. 1998;7(5):783–90.
13.
RubinszteinDC, WyttenbachA, RankinJ. Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?J Med Genet. 1999;36(4):265–70.
14.
RankinJ, WyttenbachA, RubinszteinDC. Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death. Biochem J. 2000;15(Pt1):15–9.
15.
SaudouF, FinkbeinerS, DevysD, GreenbergME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95(1):55–66.
16.
GutekunstCA, LiSH, YiH, MulroyJS, KuemmerleS, JonesR, et al. Nuclear and neuropil aggregates in Huntington’s disease: Relationship to neuropathology. J Neurosci. 1999;19(7):2522–34.
17.
KuemmerleS, GutekunstCA, KleinAM, LiXJ, LiSH, BealMF, et al. Huntington aggregates may not predict neuronal death in Huntington’s disease. Ann Neurol. 1999;46(6):842–9.
18.
HanssonO, GuatteoE, MercuriNB, BernardiG, LiXJ, CastilhoRF, et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci. 2001;14(9):1492–504.
19.
ArrasateM, MitraS, SchweitzerES, SegalMR, FinkbeinerS. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805–10.
20.
GongB, LimMC, WandererJ, WyttenbachA, MortonAJ. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington’s disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res Bull. 2008;75(1):146–57.
21.
MillerJ, ArrasateM, ShabyBA, MitraS, MasliahE, FinkbeinerS. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington’s disease molecular pathogenesis. J Neurosci. 2010;30(31):10541–50.
22.
DuennwaldML. Polyglutamine misfolding in yeast: Toxic and protective aggregation. Prion. 2011;5(4):285–90.
23.
YoungD, MayerF, VidottoN, SchweizerT, BerthR, AbramowskiD, et al. Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice. PLoS One. 2013;8(9):e75108.
24.
BersukerK, HippMS, CalaminiB, MorimotoRI, KopitoRR. Heat shock response activation exacerbates inclusion body formation in a cellular model of Huntington disease. J Biol Chem. 2013;288(33):23633–8.
25.
WandererJ, MortonAJ. Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington’s disease. Histochem. Cell Biol. 2007;127(5):473–84.
26.
CaronNS, HungCL, AtwalRS, TruantR. Live cell imaging and biophotonic methods reveal two types of mutant huntingtin inclusions. Hum Mol Genet. 2014;23(9):2324–38.
27.
BecherMW, KotzukJA, SharpAH, DaviesSW, BatesGP, PriceDL, et al. Intranuclear neuronal inclusions in Huntington’s disease and dentatorubral and pallido- luysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis. 1998;4(6):387–97.
28.
RübU, HentschelM, StratmannK, BruntE, HeinsenH, SeidelK, et al. Huntington’s disease (HD): Degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem. Brain Pathol. 2014;24:247–60.
29.
MangiariniL, SathasivamK, SellerM, CozensB, HarperA, HetheringtonC, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493–506.
30.
GundersenHJ, JensenEB. The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987;147(Pt3):229–63.
31.
GundersenHJ. The efficiency of systematic sampling in stereology–reconsidered. J Microsc. 1999;193(Pt 3):199–211.
32.
BoyceRW, Dorph-PetersenKA, LyckL, GundersenHJ. Design-based stereology: Introduction to basic concepts and practical approaches for estimation of cell number. Toxicol Pathol. 2010;38(7):1011–25.
33.
Cruz-OriveLM. Stereology of single objects. 1997 J Microsc. 1997;186(2):93–107.
34.
BraendgaardH, GundersenHJ. The impact of recent stereological advances on quantitative studies of the nervous system. J Neurosci Methods. 1986;18(1-2):39–78.
35.
WestMJ, SlomiankaL, GundersenHJ. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec. 1991;231(4):482–97.
36.
MeadeCA, DengYP, FuscoFR, Del MarN, HerschS, GoldowitzD, et al. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J Comp Neurol. 2002;449(3):241–69.
37.
GongB, KielarC, MortonAJ. Temporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington’s disease mutation. PLoS One. 2012;7(7):e41450.
38.
SawiakSJ, WoodNI, WilliamsGB, MortonAJ, CarpenterTA. Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington’s disease. Neurobiol Dis. 2009;33(1):12–9.
39.
DaviesSW, TurmaineM, CozensBA, DiFigliaM, SharpAH, RossCA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537–48.
40.
WheelerVC, AuerbachW, WhiteJK, SrinidhiJ, AuerbachA, RyanA, et al. Length-dependent gametic CAG repeat instability in the Huntington’s disease knock-in mouse. Hum Mol Genet. 1999;8(1):115–22.
41.
WheelerVC, LebelLA, VrbanacV, TeedA, te RieleH, MacDonaldME. Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. Hum Mol Genet. 2003;12(3):273–81.
42.
MenalledLB, SisonJD, DragatsisI, ZeitlinS, ChesseletMF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11–26.
43.
van RaamsdonkJM, MurphyZ, SlowEJ, LeavittBR, HaydenMR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet. 2005;14(24):3823–35.
44.
Maat-SchiemanML, DorsmanJC, SmoorMA, SieslingS, Van DuinenSG, VerschuurenJJ, et al. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J Neuropathol Exp Neurol. 1999;58(2):129–37.
LiH, LiSH, ChengAL, MangiariniL, BatesGP, LiXJ. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington’s disease transgenic mice. Hum Mol Genet. 1999;8(7):1227–36.
47.
DragatsisI, GoldowitzD, Del MarN, DengYP, MeadeCA, LiuL, et al. CAG repeat lengths >or=335 attenuate the phenotype in the R6/2 Huntington’s disease transgenic mouse. Neurobiol Dis. 2009;33(3):315–30.
48.
CaronNS, HungCL, AtwalRS, TruantR. Live cell imaging and biophotonic methods reveal two types of mutant huntingtin inclusions. Hum Mol Gen. 2014;23:2324–38.
49.
DuzdevichD, LiJ, WhangJ, TakahashiH, TakeyasuK, DrydenDTF, et al. Unusual structures are present in DNA fragments containing super-long Huntingtin CAG repeats. PLoS One. 2011;6(2):e17119.
50.
GrahamRK, DengY, SlowEJ, HaighB, BissadaN, LuG, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125(6):1179–91.
51.
SlowEJ, GrahamRK, OsmandAP, DevonRS, LuG, DengY, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A. 2005;102(32):11402–7.
52.
Tomas-ZapicoC, Díez-ZaeraM, FerrerI, Gómez-RamosP, MoránMA, Miras-PortugalMT, et al. α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington’s disease. Hum Mol Genet. 2012;21(3):495–510.
53.
CharlesV, MezeyE, ReddyPH, DehejiaA, YoungTA, PolymeropoulosMH, et al. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s disease patients and transgenic mouse models. Neurosci Lett. 2000;289:29–32.
54.
BlumD, HerreraF, FrancelleL, MendesT, BasquinM, ObriotH, et al. Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Hum Mol Genet. 2014;24(1):76–85.
55.
YuZX, LiSH, EvansJ, PillarisettiA, LiH, LiXJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington’s disease. J Neurosci. 2003;23(6):2193–202.
56.
HengMY, Tallaksen-GreeneJS, DetloffPJ, AlbinRL. Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington’s disease. J Neurosci. 2007;27(34):8989–98.
57.
WoodmanB, ButlerR, LandlesC, LuptonMK, TseJ, HocklyE, et al. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull. 2007;72(2-3):83–97.
58.
GrayM, ShirasakiDI, CepedaC, AndréVM, WilburnB, LuXH, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28(24):6182–95.
59.
TurmaineM, RazaA, MahalA, MangiariniL, BatesGP, DaviesSW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington’s disease. Proc Natl Acad Sci U S A. 2000;97(14):8093–7.
60.
MoffittH, McPhailGD, WoodmanB, HobbsC, BatesGP. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington’s disease. PLoS One. 2009;4(11):e8025.
61.
MaywoodES, FraenkelE, McAllisterCJ, WoodN, ReddyAB, HastingsMH, et al. Disruption of peripheral circadian timekeeping in a mouse model of Huntington’s disease and its restoration by temporally scheduled feeding. J Neurosci. 2010;30(30):10199–204.
62.
WoodNI, SawiakSJ, BuonincontriG, NiuY, KaneAD, CarpenterTA, et al. Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington’s disease. J Huntingtons Dis. 2012;1(1):57–64.
63.
Magnusson-LindA, DavidssonM, SilajdžićE, HansenC, McCourtAC, TabriziSJ, et al. Skeletal muscle atrophy in R6/2 mice - altered circulating skeletal muscle markers and gene expression profile changes. J Huntingtons Dis. 2014;3(1):13–24.
64.
LarsonE, FyfeI, MortonAJ, MoncktonDG. Age-, tissue- and length-dependent bidirectional somatic CAG•CTG repeat instability in an allelic series of R6/2 Huntington disease mice. Neurobiol Dis. 2015;76:98–111.
65.
McCourtAC, JakobssonL, LarssonS, HolmC, PielS, ElmérE, et al. White adipose tissue browning in the R6/2 mouse model of Huntington’s disease. PLoS One. 2016;11(8):e0159870.
66.
TrushinaE, DyerRB, BadgerJD, UreD, EideL, TranDD, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol. 2004;24(18):8195–209.
67.
StackEC, DedeogluA, SmithKM, CormierK, KubilusJK, BogdanovM, et al. Neuroprotective effects of synaptic modulation in Huntington’s disease R6/2 mice. J Neurosci. 2007;27(47):12908–15.
68.
MilnerwoodAJ, RaymondLA. Corticostriatal synaptic function in mouse models of Huntington’s disease: Early effects of huntingtin repeat length and protein load. J Physiol. 200;585(Pt3):817–31.
CalabreseV, ScapagniniG, Giuffrida StellaAM, BatesTE, ClarkJB. Mitochondrial involvement in brain function and dysfunction: Relevance to aging, neurodegenerative disorders and longevity. Neurochem Res. 2001;26(6):739–64.
71.
Acevedo-TorresK, BerríosL, RosarioN, DufaultV, SkatchkovS, EatonMJ, et al. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington’s disease. DNA Repair (Amst). 2009;8(1):126–36.
72.
KimJ, MoodyJP, EdgerlyCK, BordiukOL, CormierK, SmithK, et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet. 2010;19(20):3919–35.
73.
SquitieriF, FalleniA, CannellaM, OrobelloS, FulceriF, LenziP, et al. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm. 2010;117(1):77–83.
74.
CostaV, GiacomelloM, HudecR, LopreiatoR, ErmakG, LimD, et al. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli. EMBO Mol Med. 2010;2(12):487–9.
75.
WangH, LimPJ, KarbowskiM, MonteiroMJ. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet. 2009;18(4):737–52.
76.
RosasHD, KoroshetzWJ, ChenYI, SkeuseC, VangelM, CudkowiczME, et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology. 2003;60(10):1615–20.
77.
KassubekJ, GausW, LandwehrmeyerGB. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology. 2004;62(3):523–4.
78.
AylwardEH, BrandtJ, CodoriAM, MangusRS, BartaPE, HarrisGJ. Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology. 1994;44(5):823–8.
79.
HarrisGJ, CodoriAM, LewisRF, SchmidtE, BediA, BrandtJ. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington’s disease. Brain. 1999;122(Pt9):1667–78.
80.
MajidDS, AronAR, ThompsonW, SheldonS, HamzaS, StoffersD, et al. Basal ganglia atrophy in prodromal Huntington’s disease is detectable over one year using automated segmentation. Mov Disord. 2011;26(14):2544–51.
81.
van den BogaardSJ, DumasEM, AcharyaTP, JohnsonH, LangbehnDR, ScahillRI, et al. Early atrophy of pallidum and accumbens nucleus in Huntington’s disease. J Neurol. 2011;258(3):412–20.
82.
van den BogaardSJ, DumasEM, HartEP, MillesJ, ReilmannR, StoutJC, et al. Magnetization transfer imaging in premanifest and manifest huntington disease: A 2-year follow-up. AJNR Am J Neuroradiol. 2013;34(2):317–22.
83.
TabriziSJ, ScahillRI, OwenG, DurrA, LeavittBR, RoosRA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637–49.
84.
AlbinRL. Selective neurodegeneration in Huntington’s disease. Ann Neurol. 1995;38(6):835–6.
85.
Gómez-TortosaE, MacDonaldME, FriendJC, TaylorSA, WeilerLJ, CupplesLA, et al. Quantitative neuropathological changes in presymptomatic Huntington’s disease. Ann Neurol. 2001;49(1):29–34.
